A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens stem transplant, leaving them limited options. Targeted therapies, including Bruton tyrosine kinase inhibitors, effective treatment strategy in mantle lymphoma. Zanubrutinib a potent next-generation inhibitor that has demonstrated complete sustained occupancy, minimal off-target effects favorable pharmacokinetic/pharmacodynamic properties. Described herein ongoing Phase III study comparing efficacy safety of zanubrutinib plus rituximab followed by monotherapy versus bendamustine observation transplant-ineligible patients previously untreated Clinical Trial Registration: NCT04002297 ( ClinicalTrials.gov )